Table 3.
The clinicopathological characteristics of the study group.
| Characteristics | Frequencies (%) |
|---|---|
| Age | |
| 30–40 years | 35 |
| 41–50 years | 65 |
| Pathological tumor size (pT) | |
| T1a | 68 |
| T1b | 32 |
| Pathological lymph node involvement (N) | |
| negative (N0) | 55 |
| positive (N1) | 45 |
| Estrogen receptor (ER) | |
| negative | 43 |
| positive | 57 |
| Progesterone receptor (PR) | |
| negative | 52 |
| positive | 48 |
| Human epidermal growth factor receptor 2 (HER2) | |
| negative | 78 |
| positive | 22 |
| Tumor grade (G) | |
| G1 and G2 | 71 |
| G3 | 29 |
| Progress | |
| absent | 69 |
| present | 31 |
| Metastasis | |
| absent | 74 |
| present | 26 |
| Death | |
| absent | 78 |
| present | 22 |
T1a—>1 mm but ≤5 mm, T1b—>5 mm but ≤10 mm across, G1—well differentiated (low grade), G2—moderately differentiated (intermediate grade), G3—poorly differentiated.